[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ctdna\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ctdna":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,46,72,95,111,126,144,169,195,219,240,260,288,316,338,361],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100538199","french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-frenchmrdcrlm-100538199",false,"NCT06287723","French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Colorectal With Liver Metastasis Patients","Inclusion Criteria:\n\n* Patient 18 years or older.\n* Colorectal cancer liver metastasis or metastases, according to the assessment of the MDT.\n* Metachronous and synchronous metastases will be included, as long as treatment intention of metastases resection is curative. In case of rare instances, where the liver metastases is removed before surgery of the primary tumor, postOP ctDNA is collected when the patient is considered completely tumor-free, i.e. after complete surgery of both the liver metastases and the primary tumor.\n* Treatment is planned with curative intent (patients treated with RFA can be included, BUT in these cases a tissue sample from the primary CRC tumor is a requisite)\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Extrahepatic metastases\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Liver cirrhosis\n* CRLM intervention\u002Fsurgery cannot be\u002Fwas not performed with curative intent\n* No tumor tissue available (preferably CRLM lesion, or alternatively primary tumor)\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project.",[24,25,26,27,28,29],"Colorectal Cancer","Liver Metastases","Stage IV Colorectal Cancer","Minimal Residual Disease","Liquid Biopsy","ctDNA",[31,27,32],"Stage IV colorectal cancer","Liquid biopsy","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":37},"2024-04-15",{"date":41,"type":20},"2029-04-15",{"name":43,"class":44},"University Hospital, Montpellier","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100603404","phase-2-a-phase-2-trial-of-fruquintinib-and-tislelizumab-in-ctdna-defined-minimal-residual-disease-in-colorectal-cancer-after-completion-of-adjuvant-chemotherapy-100603404","NCT07136077","A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","Eligibility Criteria\n\n* Participants must have histologically or cytologically confirmed microsatellite stable (MSS) colorectal adenocarcinoma.\n* Participants must have completed curative intent treatments of stages II, III, or IV colorectal cancer that must include ≥ 3 months of oxaliplatin containing chemotherapy.\n* No evidence of radiographic disease within 28 days (before or after) a positive ctDNA assay.\n* Participants must have minimal residual disease as defined by positive ctDNA assay by Signatera MRD assay.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Absolute neutrophil count of ≥1.0×109\u002FL\n  * Platelet count of ≥100×109\u002FL\n  * Hemoglobin ≥9 g\u002FdL\n  * Serum total bilirubin ≤1.5× upper limit of normal (ULN) (total bilirubin must be \\\u003C3× ULN for participants with documented Gilbert's syndrome).\n  * Participants must have ALT and AST ≤5× ULN.\n  * Urine protein ≤1+ by dipstick or 24-hour urine protein \\\u003C1 g\u002F24 hours. Participants with 2+ proteinuria by dipstick must undergo 24-hour urine collection to assess urine protein level.\n  * Creatinine creatinine clearance (CrCl) ≥30 mL\u002Fmin per Cockcroft-Gault.\n  * International normalized ratio (INR) and activated prothrombin time (aPTT) ≤1.5 ULN unless the participant is receiving anticoagulation therapy and INR and aPTT values are within the intended therapeutic range.\n* ECOG performance status (PS) of 0 or 1.\n* Age ≥ 18 years.\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months after the end of study treatment. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n  * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n  * History of hysterectomy or bilateral salpingo-oophorectomy.\n  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n  * History of bilateral tubal ligation or another surgical sterilization procedure.\n* Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study treatment administration.\n* Is able to understand and is willing to sign a written informed consent document.\n\nExclusion Criteria\n\n* Has other concomitant active, invasive malignancies that may interfere with ctDNA analysis (known clonal hematopoesis of unknown potential allowed).\n* Has serum electrolytes, potassium, calcium, or magnesium levels outside of the normal laboratory reference range which are clinically significant in the investigator's judgment.\n* Has significant concomitant health conditions including but not limited to severe autoimmune or cardiovascular disorders that may interfere with participation in the study.\n* Active autoimmune diseases or history of autoimmune diseases that may worsen or relapse per treating providers' evaluation.\n* Has a persistent adverse event from previous treatment, except alopecia and neuropathy, greater than or equal to grade 2 of the Common Toxicity Criteria for Adverse Events (CTCAE) v. 5.0\n* Systemic anti-neoplastic therapies or any investigational therapy within 4 weeks prior to the first dose of study drug, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy, and immunotherapy.\n* Systemic small molecule-targeted therapies (eg, tyrosine kinase inhibitors) within 5 halflives or 4 weeks (whichever is shorter) prior to the first dose of study drug.\n* Mean QT interval corrected by the method of Fridericia (QTcF) ≥480 ms.\n* Has another disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition that investigators suspect may (a) prohibit use of the investigational product, (b) affect interpretation of study results, or (c) put the participant at undue risk of harm\n* Has known hypersensitivity to the trial drugs or their excipients or is at risk of allergic of anaphylactic reaction to drug product according to the Investigator's judgement.\n* Is pregnant or lactating.\n* Is unable to take medication orally or has any other condition that investigators believe may affect absorption of the investigational product.\n* Is receiving any other investigational agent.\n* Any condition that requires systemic treatment with either corticosteroid (\\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the first dose of study drug(s), with the following exceptions:\n\n  * Adrenal replacement (dose of ≤10 mg daily of prednisone or equivalent).\n  * Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption.\n  * Short course (≤7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen)\n* Live vaccine ≤28 days before the first dose of study drug(s). Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.\n* Known untreated or inadequately treated active hepatitis C, or chronic hepatitis B.\n* Known untreated or inadequately treated human immunodeficiency virus (HIV) infection.\n* Major surgery within 30 days before the first drug administration. Participants must have recovered adequately from the toxicity and\u002For complications from the intervention prior to the first dose of study drug(s).\n* Prior allogeneic stem cell transplantation or organ transplantation.\n* Any of the following cardiovascular risk factors:\n\n  * Acute myocardial infarction ≤6 months before the first dose of study drug(s).\n  * Heart failure meeting New York Heart Association Function Classification III or IV ≤6 months before the first dose of study drug(s)\n  * Ventricular arrhythmia Grade ≥2 in severity ≤6 months before the first dose of study drug(s).\n  * Cerebrovascular accident ≤12 months before the first dose of study drug(s).\n  * Uncontrolled hypertension that cannot be managed by standard antihypertension medications, which is specified as systolic pressure ≥140 mmHg and\u002For diastolic pressure ≥90 mmHg. The participant must have blood pressures below both limits. Repeated assessments are permitted.\n  * Syncope or seizure ≤28 days before the first dose of study drug(s).\n* Received strong inducers of cytochrome P450, family 3, subfamily A (CYP3A) taken within 2 weeks (or 5 times the t1\u002F2 of the drug, whichever is longer) prior to the first study treatment.\n* Active gastrointestinal and duodenal ulcers, ulcerative colitis, and other gastrointestinal disease: other conditions that the investigator determines to possibly cause gastrointestinal bleeding, perforation, and other conditions; or prior gastrointestinal perforation or gastrointestinal fistula that has not recovered after surgical treatment.\n* History or presence of clinically significant hemorrhage from any site (such as clinically significant melena, hematemesis, hemoptysis, fresh in stool) within 2 months before the screening.\n* History of arterial thrombus within the last 12 months.",{"count":53,"type":20},20,"INTERVENTIONAL",[56],"PHASE2","To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have \"positive\" ctDNA tests for MRD (meaning there is evidence of MRD based on this test).",[27,59,24,60,61,29],"Adjuvant Chemotherapy","Fruquintinib","Tislelizumab","2026-05-28",{"date":64,"type":37},"2026-06-01",{"date":66,"type":37},"2025-09-18",{"date":68,"type":20},"2028-04-01",{"name":70,"class":44},"M.D. Anderson Cancer Center",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":71},"100636193","phase-2-randomized-trial-of-plasma-ctdna-methylation-guided-adjuvant-therapy-in-t4n0-and-low-risk-stage-iii-colorectal-cancer-100636193","NCT07562503","Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","CLEAR-03","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of sex;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of \\>3 months;\n3. Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;\n4. Positive ctDNA status at 1 month after surgery;\n5. Expected survival of \\>12 months;\n6. Ability to understand and willingness to sign a written informed consent form (personally or via a legally authorized representative\u002Fguardian), indicating that the subject understands the study objectives and required procedures and agrees to participate.\n\nExclusion Criteria:\n\n1. Receipt of neoadjuvant therapy prior to surgery;\n2. Blood transfusion during surgery or within 2 weeks prior to surgery;\n3. Pregnant or breastfeeding women, or individuals of reproductive potential who are not using adequate contraception;\n4. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer;\n5. Uncontrolled primary brain tumors or central nervous system metastases, or presence of significant intracranial hypertension or neuropsychiatric symptoms;\n6. Presence of severe or uncontrolled comorbidities, including but not limited to:Severe cardiac disease that remains unstable despite treatment, including myocardial infarction, congestive heart failure, unstable angina, symptomatic pericardial effusion, or unstable arrhythmia within 6 months prior to enrollment; Clearly diagnosed neurological or psychiatric disorders, including dementia or seizure disorders;Severe or uncontrolled infections;Active disseminated intravascular coagulation (DIC) or significant bleeding tendency;Significant impairment of major organ function;\n7. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.","80 Years",{"count":81,"type":20},340,[56],"The patient (T4N0 or low-risk stage III) will be randomly assigned to either the control group (FOLFOX\u002FCAPOX for 3 months) or the intervention group (FOLFOX\u002FCAPOX for 6 months or FOLFOX\u002FCAPOX for 3 months followed by FOLFIRI\u002FCAPIRI for 3 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months after surgery for dynamic monitoring of plasma ctDNA.",[29,24,85],"Chemotherapy","2026-04-26",{"date":88,"type":37},"2026-05-01",{"date":90,"type":37},"2024-11-01",{"date":92,"type":20},"2027-12-31",{"name":94,"class":44},"Fudan University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":101,"targetDuration":4,"studyType":54,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":110,"locationsCount":71},"100636192","phase-2-a-randomized-controlled-trial-of-plasma-ctdna-methylation-guided-adjuvant-chemotherapy-decision-making-in-high-risk-stage-iii-t4n-or-t1-3n2-colorectal-cancer-100636192","NCT07562490","A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer","CLEAR-04",{"count":102,"type":20},100,[56],"Patients with T4N+ or T1-3N2 disease will be randomly assigned to either the control group (FOLFOX\u002FCAPOX for 6 months) or the intervention group (FOLFOX\u002FCAPOX plus bevacizumab for 6 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months postoperatively for dynamic monitoring of plasma ctDNA.",[29,85,24],{"date":88,"type":37},{"date":108,"type":37},"2025-04-01",{"date":92,"type":20},{"name":94,"class":44},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":117,"targetDuration":4,"studyType":54,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":125,"locationsCount":71},"100636209","phase-2-randomized-study-of-plasma-ctdna-methylation-to-guide-adjuvant-chemotherapy-decisions-in-high-risk-t3n0-colorectal-cancer-100636209","NCT07562711","Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","CLEAR-02",{"count":81,"type":20},[56],"This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery. It aims to investigate the impact of different adjuvant chemotherapy regimens on ctDNA clearance rates and their prognostic significance. By using postoperative ctDNA status to identify patients at high risk of recurrence, the study seeks to implement intensified chemotherapy strategies (treatment escalation) at an early stage, thereby improving ctDNA clearance and ultimately enhancing patient outcomes",[29,85,24],"2026-04-25",{"date":88,"type":37},{"date":90,"type":37},{"date":92,"type":20},{"name":94,"class":44},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":134,"targetDuration":4,"studyType":54,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":71},"100636205","phase-2-randomized-controlled-study-of-plasma-ctdna-methylation-guided-adjuvant-chemotherapy-in-stage-ilow-risk-stage-ii-colorectal-cancer-100636205","NCT07562659","Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I\u002FLow-Risk Stage II Colorectal Cancer","A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decisions in Postoperative Stage I or Low-Risk Stage II Colorectal Cancer Patients","CLEAR-01","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Age ≥18 years, regardless of sex;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of \\>3 months;\n3. Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;\n4. Positive ctDNA status at 1 month after surgery;\n5. Expected survival of \\>12 months;\n6. Ability to understand and willingness to sign a written informed consent form (personally or via a legally authorized representative\u002Fguardian), indicating that the subject understands the study objectives and required procedures and agrees to participate.\n\nExclusion Criteria:\n\n1. Receipt of neoadjuvant therapy prior to surgery;\n2. Blood transfusion during surgery or within 2 weeks prior to surgery;\n3. Pregnant or breastfeeding women, or individuals of reproductive potential who are not using adequate contraception;\n4. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer;\n5. Uncontrolled primary brain tumors or central nervous system metastases, or presence of significant intracranial hypertension or neuropsychiatric symptoms;\n6. Presence of severe or uncontrolled comorbidities, including but not limited to:Severe cardiac disease that remains unstable despite treatment, including myocardial infarction, congestive heart failure, unstable angina, symptomatic pericardial effusion, or unstable arrhythmia within 6 months prior to enrollment; Clearly diagnosed neurological or psychiatric disorders, including dementia or seizure disorders;Severe or uncontrolled infections;Active disseminated intravascular coagulation (DIC) or significant bleeding tendency;Significant impairment of major organ function; Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.",{"count":135,"type":20},80,[56],"This study will utilize ctDNA methylation detection to evaluate patients with stage I or low-risk stage II colorectal cancer who are ctDNA-positive one month after surgery. It aims to investigate the impact of different adjuvant chemotherapy regimens on ctDNA clearance rates and their prognostic significance. By using postoperative ctDNA status to identify patients at high risk of recurrence, the study seeks to implement intensified chemotherapy strategies (treatment escalation) at an early stage, thereby improving ctDNA clearance and ultimately enhancing patient outcomes.",[29,139,59],"Colorectal Cancer (CRC)",{"date":88,"type":37},{"date":90,"type":37},{"date":92,"type":20},{"name":94,"class":44},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":54,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100631994","phase-2-dynamic-ctdna-guided-adjuvant-therapy-in-cstage-iii-and-iva-gastric-or-gastroesophageal-junction-adenocarcinoma-100631994","NCT07507916","Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma","Dynamic Circulating Tumor DNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma：A Phase 2 Clinical Trial","Inclusion Criteria:\n\n1. Voluntarily participate in the study; fully understand the study and sign the written informed consent form (ICF); be willing and able to comply with all study procedures.\n2. Male or female patients aged ≥18 years and ≤75 years at the time of signing the ICF.\n3. Histologically confirmed, previously untreated gastric cancer or gastroesophageal junction (GEJ) cancer, with adenocarcinoma as the predominant histology. For GEJ cancer, only Siewert type III and Siewert type II tumors not requiring thoracotomy are eligible.\n4. Clinically confirmed stage III or stage IVA disease without distant metastasis, as assessed by the treating physician prior to enrollment.\n5. HER2-negative disease.\n6. Adequate cardiac function and deemed suitable for curative-intent surgical resection. Patients with ischemic heart disease, valvular disease, or other significant cardiac conditions should undergo preoperative evaluation by a cardiologist if clinically indicated.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to enrollment.\n8. Estimated life expectancy of at least 6 months.\n9. Negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core antibody (HBcAb). If HBsAg-positive or HBcAb-positive, hepatitis B virus DNA (HBV-DNA) must be \\\u003C1000 copies\u002FmL, \\\u003C200 IU\u002FmL, or below the upper limit of normal (ULN) of the study center.\n10. Negative hepatitis C virus (HCV) antibody.\n11. Adequate organ function, defined as follows (without transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factors within 14 days prior to randomization):\n\n    Hematologic function\n    * Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL\n    * Platelet count ≥ 100 × 10⁹\u002FL\n    * Hemoglobin ≥ 90 g\u002FL Hepatic function\n    * Total bilirubin ≤ 1.5 × ULN\n    * ALT ≤ 2.5 × ULN (≤ 5.0 × ULN in patients with liver metastases)\n    * AST ≤ 2.5 × ULN (≤ 5.0 × ULN in patients with liver metastases)\n    * Alkaline phosphatase ≤ 2.5 × ULN (≤ 5.0 × ULN in patients with liver and\u002For bone metastases)\n    * Albumin ≥ 25 g\u002FL Renal function\n    * Creatinine clearance ≥ 50 mL\u002Fmin (calculated by the Cockcroft-Gault formula) Coagulation function\n    * Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN\n    * Prothrombin time (PT) ≤ 1.5 × ULN\n    * International normalized ratio (INR) ≤ 1.5 × ULN\n12. Female patients must meet one of the following:\n\n    * Postmenopausal (defined as ≥1 year without menstruation not due to other causes), or\n    * Surgically sterile (bilateral oophorectomy and\u002For hysterectomy), or\n    * Of childbearing potential and meeting all of the following:\n    * Negative serum pregnancy test within 7 days prior to enrollment;\n    * Agree to use highly effective contraception (annual failure rate \\\u003C1%) or remain abstinent from signing the ICF until at least 120 days after the last dose of study drug and 6 months after the last dose of chemotherapy;\n    * Not breastfeeding.\n13. Male patients must agree to abstain from heterosexual intercourse or use effective contraception during chemotherapy and for at least 6 months after the last dose of chemotherapy, and for at least 120 days after the last dose of study drug, if their partner is of childbearing potential or pregnant.\n\nExclusion Criteria:\n\n1. History of another active malignancy within the past 5 years or concurrent malignancy, except for cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervix, or breast.\n2. Presence of distant metastasis (M1) from gastric cancer.\n3. Prior or planned organ or bone marrow transplantation.\n4. History of myocardial infarction within 6 months prior to enrollment, or poorly controlled arrhythmia, including QTc prolongation (QTc ≥450 ms in males or ≥470 ms in females, calculated using Fridericia's formula).\n5. New York Heart Association (NYHA) class III-IV heart failure, or left ventricular ejection fraction (LVEF) \\\u003C50% on echocardiography.\n6. Known human immunodeficiency virus (HIV) infection.\n7. Active pulmonary tuberculosis.\n8. Current or prior interstitial lung disease, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severe pulmonary dysfunction that may interfere with the assessment or management of suspected drug-related pulmonary toxicity.\n9. Known active or suspected autoimmune disease, except for patients with stable disease not requiring systemic immunosuppressive therapy at enrollment.\n10. Receipt of a live vaccine within 28 days prior to enrollment (seasonal influenza vaccines with inactivated virus are allowed).\n11. Requirement for systemic corticosteroids (\\>10 mg\u002Fday prednisone equivalent) or other immunosuppressive therapy within 14 days prior to enrollment or during the study, except for:\n\n    * Topical or inhaled corticosteroids;\n    * Physiologic replacement therapy with prednisone ≤10 mg\u002Fday in the absence of active autoimmune disease.\n12. Active infection requiring systemic anti-infective therapy within 14 days prior to enrollment (prophylactic antibiotics, such as for urinary tract infection or chronic obstructive pulmonary disease, are allowed).\n13. Prior treatment with immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies.\n14. Participation in another clinical study or receipt of investigational treatment within 14 days prior to initiation of this study.\n15. Known severe hypersensitivity to any monoclonal antibody or components of the study drugs.\n16. History of substance abuse or illicit drug use; patients who have stopped alcohol consumption may be enrolled.\n17. Any condition that, in the investigator's judgment, may increase the risk of study participation or interfere with study treatment, compliance, or evaluation.","75 Years",{"count":153,"type":20},32,[56],"This is a single-center, prospective, exploratory study evaluating the use of dynamic circulating tumor DNA (ctDNA) monitoring in the postoperative adjuvant treatment setting for patients with stage III or stage IVA gastric or gastroesophageal junction adenocarcinoma.\n\nAfter curative-intent surgery, patients remain at risk of disease recurrence. Postoperative treatment decisions are currently based on clinicopathological factors, which may not fully reflect minimal residual disease. ctDNA is a blood-based biomarker that can detect tumor-derived DNA fragments and may provide additional information on recurrence risk.\n\nIn this study, ctDNA will be assessed at predefined perioperative and postoperative time points using peripheral blood samples. The primary objective is to evaluate 1-year disease-free survival. Secondary objectives include survival outcomes, safety, and longitudinal changes in ctDNA status. The findings of this exploratory study may inform future research on ctDNA-guided postoperative management in gastric cancer.",[29,157,158,159],"Gastric Cancer","Gastroesophageal Junction (GEJ) Adenocarcinoma","Adjuvant Treatment","NOT_YET_RECRUITING","2026-03-30",{"date":163,"type":37},"2026-04-02",{"date":165,"type":20},"2026-04-01",{"date":167,"type":20},"2029-12-31",{"name":94,"class":44},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":151,"enrollmentInfo":175,"targetDuration":4,"studyType":54,"phases":176,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":45},"100577014","a-multicenter-prospective-study-evaluating-concurrent-chemoradiotherapy-following-induction-immunochemotherapy-for-esophageal-cancer-based-on-dynamic-ctdna-monitoring-100577014","NCT06792786","A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring","Inclusion Criteria:\n\n* All subjects must sign an informed consent form before initiating any study-related procedures;\n* All patients must be aged ≥18 years and ≤75 years;\n* Histologically or cytologically confirmed esophageal cancer (squamous cell carcinoma);\n* Clinical stage II-IVa, assessed by a surgeon as inoperable, or patient refusal of surgery;\n* No prior radiotherapy, chemotherapy, immunotherapy, or biotherapy for esophageal cancer;\n* ECOG performance status of 0-1;\n* Laboratory test values within the following limits before the first dose of the investigational drug:\n* Hematology: WBC ≥3.0×10⁹\u002FL; ANC ≥1.5×10⁹\u002FL; PLT ≥70×10⁹\u002FL; HGB ≥9.0 g\u002FdL;\n* Liver function: AST ≤2.5×ULN; ALT ≤2.5×ULN;\n* Renal function: Cr ≤1.5×ULN or CrCl ≥40 mL\u002Fmin;\n* Coagulation: INR ≤1.5, APTT ≤1.5×ULN;\n* Other: Lipase ≤1.5×ULN, unless clinically\u002Fradiographically insignificant if lipase \\>1.5×ULN.\n\nExclusion Criteria:\n\n* Insufficient tissue\u002Fblood sample available before treatment as required for the study;\n* Patient refusal to undergo dynamic ctDNA testing;\n* The primary esophageal lesion is in close proximity to the tracheobronchial tree or major blood vessels, with an investigator-assessed high risk of perforation or major hemorrhage;\n* History of malignancies other than esophageal carcinoma within the past 5 years (except for curatively treated localized tumors such as carcinoma in situ of the cervix, basal cell carcinoma, or localized prostate cancer);\n* History of gastrointestinal bleeding within the past 6 months, or coagulopathy at enrollment, or current thrombolytic or anticoagulant therapy indicating a high risk of bleeding;\n* Severe cardiovascular or cerebrovascular diseases;\n* History of interstitial lung disease or active pneumonia\u002Ftuberculosis;\n* Severe allergic reactions to paclitaxel\u002Fcisplatin or any monoclonal antibody;\n* Any other condition deemed inappropriate for participation in this study as judged by the investigator.",{"count":19,"type":20},[177],"NA","Esophageal squamous cell carcinoma (ESCC) continues to exhibit high incidence and mortality rates in China, with the majority of patients diagnosed at middle to advanced stages. Concurrent chemoradiotherapy (CCRT) is the standard treatment for unresectable locally advanced ESCC. The 5-year survival rate for advanced esophageal cancer remains below 20%. Immunotherapy has demonstrated definitive efficacy and a favorable toxicity profile in advanced ESCC, and preliminary results of its combination with radiotherapy have been reported. Induction immunochemotherapy followed by concurrent chemoradiotherapy represents a feasible combined treatment strategy. However, optimal biomarkers to identify patients who would benefit from this approach are still lacking. Circulating tumor DNA (ctDNA) status can accurately guide treatment implementation and predict tumor progression. Studies have shown that ctDNA changes precede imaging evidence of recurrence or metastasis, and ctDNA detection can sensitively predict tumor progression and prognosis. Therefore, it is necessary to dynamically monitor ctDNA changes throughout the course of induction immunochemotherapy followed by radical concurrent chemoradiotherapy in esophageal cancer and explore its correlation with prognosis.",[180,29],"Esophageal Cancer",[182,29,183,184,185],"esophageal cancer","chemoradiotherapy","induction immunochemotherapy","prognosis","2026-03-19",{"date":188,"type":37},"2026-03-23",{"date":190,"type":37},"2024-12-10",{"date":192,"type":20},"2027-12-30",{"name":194,"class":44},"The Central Hospital of Lishui City",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":54,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":215,"leadSponsor":217,"locationsCount":4},"100629748","early-detection-of-metastatic-recurrence-among-patients-with-stage-ii-or-iii-triple-negative-breast-cancer-using-liquid-biopsy-and-imaging-100629748","NCT07478705","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer (TNBC) Using Liquid Biopsy and Imaging: A Multi-Center Pilot Randomized Trial (EINSTEIN-TNBC)","EINSTEIN-TNBC","Inclusion Criteria:\n\n* Men or women aged 18 and over\n* Biopsy proven invasive triple negative breast cancer (defined here as estrogen receptor \\\u003C10%, progesterone receptor \\\u003C10%, human epidermal growth factor receptor 2 (HER2) negative status, with HER2 status being defined as per ASCO\u002FCAP guidelines)\n* T2-4\u002FN0 (\\>2 cm primary breast cancer as assessed clinically or on imaging in the absence of nodal involvement) OR T1c-4\u002FN1-3 disease (\\>10mm with fine needle aspirate or core biopsy confirming nodal involvement is required)\n* Residual disease (RCB 2 or 3) on surgical specimen after completion of neoadjuvant chemo(-immuno)therapy\n\nExclusion Criteria:\n\n* Inability to provide informed consent. Participants who require translators are allowed to enroll\n* Prior history of invasive breast cancer -Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the detection of BC recurrence on a liquid biopsy (patients with a history of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma-in-situ of cervix are permitted to participate)-\n* Pregnant patients are not permitted\n* Creatinine clearance \\\u003C45 mL\u002Fmin using the Cockcroft-Gault equation.",{"count":19,"type":20},[177],"Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, often with poor outcomes. Currently, follow-up for TNBC consists of physical exams and annual breast imaging, with additional scans only if symptoms appear. This approach may delay the detection of the cancer coming back until the disease is advanced.\n\nA promising new technique is the detection of circulating tumor DNA (ctDNA)-in the blood. Studies suggest ctDNA may identify cancer recurrence months before it becomes visible on scans or causes symptoms. However, it is unknown whether detecting recurrence earlier can actually help patients live longer or feel better.\n\nThe EINSTEIN-TNBC trial is a study aiming to evaluate the feasibility of ctDNA-guided surveillance for patients with TNBC after surgery.\n\nThirty participants will be randomized to either:\n\nStandard of care (routine physical exams and annual breast imaging), or Active surveillance (standard of care plus ctDNA testing, with imaging investigations if ctDNA is detected).\n\nThis study will assess the feasibility of conducting a ctDNA-based monitoring trial in this patient population.\n\nIf feasible, EINSTEIN-TNBC will lay the foundation for a larger future clinical trial to determine whether earlier detection of metastatic TNBC can improve survival and quality of life.",[207,208,209,29],"Triple Negative Breast Cancer","Surveillance","Recurrence",[29,207,208,209],"2026-03-13",{"date":213,"type":37},"2026-03-17",{"date":88,"type":20},{"date":216,"type":20},"2029-05-01",{"name":218,"class":44},"Sunnybrook Health Sciences Centre",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":151,"enrollmentInfo":226,"targetDuration":4,"studyType":54,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":71},"100623252","phase-2-ctdna-guided-treatment-decision-making-100623252","NCT07394218","ctDNA-guided Treatment Decision-making","Study on ctDNA-guided Treatment Decision-making for HER2-negative Metastatic Breast Cancer","Inclusion Criteria:\n\n* Age 18-75 years；ECOG performance status 0-1； Histologically or cytologically confirmed HER2-negative metastatic breast cancer； At least one measurable lesion per RECIST v1.1； Eligible for ADC therapy； Adequate organ and bone marrow function； Life expectancy ≥3 months； Willingness to provide tumor tissue and blood samples； Signed informed consent\n\nExclusion Criteria:\n\n* Prior treatment with ADC targeting the same antigen and payload；History of grade ≥3 immune-related adverse events； Active or untreated CNS metastases； Active autoimmune disease requiring systemic therapy； Clinically significant cardiovascular disease； Active interstitial lung disease； Active infection including tuberculosis, HIV, hepatitis B or C； Pregnancy or breastfeeding；Investigator-determined conditions that may interfere with study participation",{"count":227,"type":20},122,[56],"This is an exploratory, ctDNA-guided, multi-stage clinical study designed to evaluate the clinical value of treatment decision-making based on circulating tumor DNA (ctDNA) variant allele frequency (VAF) dynamics in patients with HER2-negative metastatic breast cancer.\n\nAll enrolled patients will receive antibody-drug conjugate (ADC) therapy for two cycles in Stage 1, with serial ctDNA assessments performed prior to Cycle 1 and Cycle 2. In Stage 2, patients without disease progression will be assigned to different treatment strategies based on the percentage reduction in mean ctDNA VAF.\n\nThe study aims to assess whether ctDNA VAF dynamics can serve as an early biomarker to guide treatment intensification and improve clinical outcomes in metastatic breast cancer.",[231,29],"Metastatic Breast Cancer ( HER2 Negative)","2026-02-01",{"date":234,"type":37},"2026-02-06",{"date":236,"type":37},"2025-12-24",{"date":238,"type":20},"2028-12-31",{"name":94,"class":44},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":71},"100612482","a-study-of-tumor-agnostic-mrd-detection-in-stage-iii-colorectal-cancer-100612482","NCT07254156","A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer","A Prospective, Multicenter, Exploratory Clinical Study Evaluating the Application of Tissue-Agnostic Technology in the Dynamic Monitoring of Minimal Residual Disease in Stage III Colorectal Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed colorectal cancer.\n* Preoperatively assessed as stage III according to the 8th edition UICC\u002FAJCC staging system.\n* Deemed eligible for radical resection upon investigator assessment.\n* No prior anti-tumor therapy received.\n* ECOG PS score 0-1.\n* Willing and able to provide signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Has a history of other malignant tumors.\n* Pregnant and lactating women.\n* Presence of any concurrent medical or psychiatric condition, as assessed by the investigator, that may interfere with protocol compliance, study follow-up, or affect short-term survival.",{"count":248,"type":20},229,"This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer. The study involves the collection of blood samples from patients who have accepted surgery for colorectal cancer. Blood samples will be analyzed using both tumor-informed and tumor-agnostic approaches to detect circulating tumor DNA (ctDNA). The study will compare the sensitivity of these methods and assess their correlation with recurrence risk. The findings aim to inform the development of optimal MRD detection strategies, ultimately providing a robust molecular basis for personalized treatment decisions.",[24,251,29],"MRD","2025-11-19",{"date":254,"type":37},"2025-11-28",{"date":256,"type":20},"2025-11-24",{"date":238,"type":20},{"name":259,"class":44},"Sun Yat-sen University",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":267,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":270,"conditions":271,"keywords":277,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":71},"100606546","a-cell-free-dna-methylation-blood-based-test-for-biliary-tract-cancers-screening-100606546","NCT07176962","A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening","A Cell-free DNA Methylation Liquid Biopsy for Diagnosis and Management of Biliary Tract Cancers","Inclusion Criteria Internal Training and Validation Cohorts\n\n* BTC patients\n\n  1. Willing to voluntarily participate and able to comply with study procedures; if unable to read or sign, informed consent must be signed by a legally authorized representative (LAR).\n  2. Age 18-80 years (inclusive).\n  3. Able to provide required blood samples.\n  4. Pathologically confirmed biliary tract carcinoma (TNM stage I-IV).\n  5. Stable vital signs; ECOG performance status 0-1.\n  6. Adequate organ function: AST\u002FALT ≤ 5 × ULN; Child-Pugh class A or B; WBC \\> 3 × 10⁹\u002FL; ANC ≥ 1.5 × 10⁹\u002FL; Platelets ≥ 75 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Creatinine clearance ≥ 60 mL\u002Fmin; Total bilirubin ≤ 3 × ULN.\n* Other gastrointestinal malignancies (to exclude BTC non-specific signals)\n\n  1. Voluntary participation with signed informed consent (or by LAR).\n  2. Age 18-80 years (inclusive).\n  3. Able to provide required blood samples.\n  4. Pathologically confirmed gastrointestinal malignancies other than BTC, including hepatocellular carcinoma, gastric cancer, colorectal cancer, and pancreatic cancer (TNM stage I-IV).\n  5. Stable vital signs; ECOG performance status 0-1.\n* Non-cancer participants (benign biliary disease)\n\n  1. Able to provide written informed consent.\n  2. Able to provide required blood samples.\n  3. Age 18-80 years (inclusive).\n  4. Pathologically or clinically diagnosed benign biliary diseases, including cholecystitis, cholelithiasis, choledocholithiasis, adenomyomatosis, gallbladder polyps, xanthogranulomatous cholecystitis, or primary sclerosing cholangitis.\n\nExternal Validation Cohorts\n\n* BTC patients\n\n  1. Voluntary participation with signed informed consent (or by LAR).\n  2. Imaging findings of malignant biliary stricture or mass, or serum CA19-9 \\> 100 U\u002FmL, highly suspicious for BTC, with planned surgery or biopsy for pathological confirmation.\n  3. Age 18-80 years (inclusive).\n  4. Able to provide required blood samples.\n  5. Stable vital signs; ECOG performance status 0-1.\n  6. Adequate organ function: AST\u002FALT ≤ 5 × ULN; Child-Pugh class A or B; WBC \\> 3 × 10⁹\u002FL; ANC ≥ 1.5 × 10⁹\u002FL; Platelets ≥ 75 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Creatinine clearance ≥ 60 mL\u002Fmin; Total bilirubin ≤ 3 × ULN.\n* Healthy volunteers\n\n  1. Able to provide written informed consent.\n  2. Able to provide required blood samples.\n  3. Age 18-80 years (inclusive).\n\nExclusion Criteria Training and Validation Cohorts\n\n* Cancer patients\n\n  1. Pregnant or breastfeeding women.\n  2. History of organ transplantation or prior allogeneic bone marrow\u002Fstem cell transplantation.\n  3. Blood transfusion within 7 days prior to blood collection.\n  4. History of curative cancer treatment within 3 years prior to blood collection.\n  5. Use of anti-tumor drugs within 30 days prior to blood collection.\n  6. Known bleeding disorders.\n  7. Known autoimmune diseases.\n  8. Concurrent other malignancies or multiple primary tumors.\n* Non-cancer participants\n\n  1. Pregnant or breastfeeding women.\n  2. History of organ transplantation or prior allogeneic bone marrow\u002Fstem cell transplantation.\n  3. Blood transfusion within 7 days prior to blood collection.\n  4. History of any malignant tumor.\n  5. Known bleeding disorders.\n  6. Known autoimmune diseases.\n  7. Clinically significant abnormalities on routine examination (excluding hepatitis, hepatic cysts, or benign pulmonary nodules).\n\nExternal Validation Cohorts\n\n* Cancer patients\n\n  1. Pregnant or breastfeeding women.\n  2. History of organ transplantation or prior allogeneic bone marrow\u002Fstem cell transplantation.\n  3. Blood transfusion within 7 days prior to blood collection.\n  4. History of or ongoing curative cancer treatment within 3 years prior to blood collection.\n  5. Use of anti-tumor drugs within 30 days prior to blood collection.\n  6. Known bleeding disorders or autoimmune diseases.\n  7. Concurrent other malignancies (including multiple primaries) or known cancer susceptibility gene carriers.\n  8. Pathology confirmed benign disease after biopsy\u002Fsurgery.\n  9. Failure to confirm malignancy by pathology or imaging within 42 days after blood collection, or unclear lesion site\u002Fevidence.\n  10. Special exclusion criteria:\n* Pathology confirmed precancerous lesions.\n* Any local\u002Fregional or systemic anti-tumor therapy (including surgery, radiotherapy, targeted therapy, or immunotherapy) prior to blood collection.\n* Healthy volunteers\n\n  1. Pregnant or breastfeeding women.\n  2. History of organ transplantation or prior allogeneic bone marrow\u002Fstem cell transplantation.\n  3. Blood transfusion within 7 days prior to blood collection.\n  4. History of any malignant tumor.\n  5. Known bleeding disorders or autoimmune diseases.\n  6. Clinically significant abnormalities on health examination (excluding hepatitis, hepatic cysts, or benign pulmonary nodules).",true,{"count":269,"type":20},1800,"Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality worldwide. Due to the lack of specific early symptoms, high malignancy, and frequent recurrence and metastasis, the rate of curative resection is only about 16.5%, and the overall 5-year survival rate is less than 5%. Early and accurate detection is therefore critical for improving patient outcomes. Circulating tumor DNA (ctDNA), a fraction of circulating free DNA (cfDNA), carries genetic and epigenetic information from tumor cells and can be detected even at the early stages of cancer development. Among various liquid biopsy biomarkers, ctDNA methylation shows particular advantages in sensitivity and specificity for early cancer detection and monitoring. This study aims to evaluate the application of cfDNA methylation liquid biopsy in the diagnosis and management of BTC.",[272,273,274,275,276,29],"Gall Bladder Cancer","Intrahepatic Cholangiocarcinoma (Icc)","Extrahepatic Cholangiocarcinoma","Hilar Cholangiocarcinoma","Billiary Track Cancer",[278,279,32,276],"ctDNA methylation","Early diagnosis","2025-09-10",{"date":282,"type":37},"2025-09-16",{"date":284,"type":37},"2020-01-01",{"date":88,"type":20},{"name":287,"class":44},"Yingbin Liu, MD, PhD, FACS",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":296,"targetDuration":298,"studyType":21,"phases":4,"briefSummary":299,"conditions":300,"keywords":305,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":71},"100602271","smc-radiation-oncology-sabr-cohort-for-oligometastasis-100602271","NCT07121335","SMC Radiation Oncology SABR Cohort for Oligometastasis","Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer","SABR-OMOP","Inclusion Criteria:\n\n* Performance status (ECOG PS) 0-2\n* Diagnosed with metastatic disease\n* Confirmed to have oligometastatic\u002Foligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)\n\nExclusion Criteria:\n\n* Patient with a history of prior radiotherapy to the site planned for SABR\n* Patients with concomitant brain metastases",{"count":297,"type":20},60,"3 Years","The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.\n\nThe main questions it aims to answer are:\n\n1. oncologic outcomes (progression-free survival, local failure rate),\n2. patient-reported outcomes,\n3. physician-assessed toxicity, and\n4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.",[301,302,303,29,304],"Stereotactic Body Radiation Therapy (SBRT)","Oligometastasis","Oligoprogression","Patient-Reported Outcomes (PRO)",[306,302,303,29],"Stereotactic body radiotherapy","2025-08-08",{"date":309,"type":37},"2025-08-13",{"date":311,"type":37},"2025-05-01",{"date":313,"type":20},"2030-03-31",{"name":315,"class":44},"Samsung Medical Center",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":71},"100538201","french-assessment-of-mrd-by-liquid-biopsies-in-pdac-patients-frenchmrdpdac-100538201","NCT06287749","French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients","Inclusion Criteria:\n\n* Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.\n* Age 18 years or older.\n* Scheduled for curative intent surgical resection.\n\nExclusion Criteria:\n\n* Hereditary pancreatic cancer.\n* Verified distant metastases.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Adult subject to a legal protection\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.",{"count":324,"type":20},37,"The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.\n\nPrimary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.\n\nSpecifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after\n\n1. curative-intended surgery and\n2. adjuvant chemotherapy.\n\nFRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project",[327,328,27,28,29],"Pancreatic Cancer Resectable","Pancreatic Ductal Adenocarcinoma",[328,327,27,28,29],"2025-07-07",{"date":332,"type":37},"2025-07-10",{"date":334,"type":37},"2024-03-01",{"date":336,"type":20},"2028-10-31",{"name":43,"class":44},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":344,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100566027","customized-circulating-tumor-dna-testing-for-cervical-cancer-recurrence-surveillance-and-treatment-decisions-100566027","NCT06649838","Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions","Inclusion Criteria:\n\n1. be willing and able to provide written informed consent\u002Fconsent for the trial.\n2. Be 18 years of age or older on the date of signing the informed consent form.\n3. patients with histologically or cytologically documented locally advanced, advanced, or first recurrent cervical cancer. For treatment-naive patients, 4) no previous cancer treatment including chemotherapy or radiotherapy; Patients with an initial recurrence had not received any other cancer treatment, including chemotherapy or radiotherapy, after the diagnosis of an initial recurrence before enrollment.\n\n5\\) measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n\n6\\) willing and able to provide tumor lesions or excisional biopsy tissue. 7) a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. Demonstrate adequate organ function.\n\n8\\) a negative pregnancy test in a fertile female patient.\n\nExclusion Criteria:\n\n1. be diagnosed as immunocompromised or receiving systemic steroid therapy or any other form of immunosuppressive therapy.\n2. a known history of active tuberculosis (Mycobacterium tuberculosis).\n3. have a known other malignancy that is progressing or requires active treatment.\n4. known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n5. have an active autoimmune disease requiring systemic treatment within the past 2 years.\n6. known history or any evidence of active noninfectious pneumonia.\n7. active infection requiring systemic therapy.\n8. there is historical or current evidence of any condition, treatment, or laboratory abnormality that could confound the trial results, interfere with the patient's participation throughout the trial, or that the treatment investigator believes participation would not be in the patient's best interest.\n9. psychiatric or substance abuse disorders known to interfere with compliance with trial requirements.\n10. be pregnant or breastfeeding, or expect to become pregnant or give birth to a child within the intended duration of the trial.\n11. had a known history of human immunovirus (HIV) (HIV 1\u002F2 antibodies).\n12. known to have active hepatitis B (e.g., HBsAg reactive) or hepatitis C.\n13. received live vaccine within 30 days of planned initiation of study treatment.","FEMALE",{"count":297,"type":20},"Immunotherapy is the main option for advanced, recurrent and metastatic cervical cancer. However, due to the complex interaction between the immune system and tumors, there is still a lack of effective markers for immunotherapy. Scientists are actively searching for and developing new immunotherapy markers. For cervical cancer diagnosis, it has been shown that ctDNA mutations can reflect HPV integration sites. In terms of cervical cancer prognosis monitoring, cohort studies focused on the application of HPV ctDNA in the field of cervical cancer prognosis monitoring. The aim of this study is to design a customized ctDNA probe for cancer patients through a priori tumor detection method, and to guide recurrence monitoring plan and implement individualized adjuvant therapy according to the results, and to explore personalized biomarkers to guide cervical cancer immunotherapy. To explore the possibility of customized ctDNA detection as a diagnostic marker for cervical cancer. To explore the predictive and prognostic value of customized ctDNA dynamic monitoring. A multi-arm cohort clinical study is planned. To comprehensively study the treatment strategy of advanced and recurrent cervical cancer and explore the related biomarkers through the customized dynamic monitoring of ctDNA in patients with advanced and recurrent cervical cancer. A total of 60 patients with cervical cancer were enrolled.",[348,349,350,351],"Immunotherapy","Cervical Cancer","CtDNA","Biomarker","2024-12-16",{"date":354,"type":37},"2024-12-19",{"date":356,"type":20},"2024-12-20",{"date":358,"type":20},"2026-10-02",{"name":360,"class":44},"Peking Union Medical College Hospital",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":71},"100570494","prognostic-study-of-via-dynamic-change-of-dt-dna-in-drainage-fluid-after-radical-prostatectomy-100570494","NCT06707974","Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy","Prognostic Study of Prostate Cancer Via Dynamic Change of Drainage Tumor DNA(dT-DNA) in Peritoneal Drainage Fluid After Radical Prostatectomy","Inclusion Criteria:\n\n* Prostate cancer patients treated with radical prostatectomy\n\nExclusion Criteria:\n\n* 1\\. Received neoadjuvant endocrine\u002Fchemotherapy before surgery;\n* 2\\. Urine leakage after surgery (positive creatinine test of drainage fluid).",{"count":102,"type":20},"This study investigates the prognostic value of dynamic changes in Drainage Tumor DNA(dT-DNA) levels found in the peritoneal drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of dT-DNA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.",[371,29],"Prostatic Neoplasms","2024-11-26",{"date":374,"type":37},"2024-11-27",{"date":376,"type":20},"2024-12-01",{"date":378,"type":20},"2025-12-01",{"name":380,"class":44},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine"]